{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,25]],"date-time":"2026-01-25T13:34:40Z","timestamp":1769348080367,"version":"3.49.0"},"reference-count":65,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,9,1]],"date-time":"2020-09-01T00:00:00Z","timestamp":1598918400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81673282"],"award-info":[{"award-number":["81673282"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81973159"],"award-info":[{"award-number":["81973159"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Scientific Research Project of Universities in Gansu Province","award":["2018A-210"],"award-info":[{"award-number":["2018A-210"]}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2020,9]]},"DOI":"10.1016\/j.neuropharm.2020.108178","type":"journal-article","created":{"date-parts":[[2020,6,13]],"date-time":"2020-06-13T19:12:18Z","timestamp":1592075538000},"page":"108178","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":9,"special_numbering":"C","title":["VF-13, a chimeric peptide of VD-hemopressin(\u03b1) and neuropeptide VF, produces potent antinociception with reduced cannabinoid-related side effects"],"prefix":"10.1016","volume":"175","author":[{"given":"Biao","family":"Xu","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jian","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kangtai","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qinqin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Run","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mengna","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hanwen","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jiandong","family":"Niu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ting","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ning","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiaoyu","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Quan","family":"Fang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2020.108178_bib1","doi-asserted-by":"crossref","first-page":"1354","DOI":"10.1038\/sj.bjp.0705896","article-title":"Anandamide acts as a vasodilator of dural blood vessels in vivo by activating TRPV1 receptors","volume":"142","author":"Akerman","year":"2004","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108178_bib2","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1001\/archgenpsychiatry.2011.161","article-title":"Induction of psychosis by Delta9-tetrahydrocannabinol reflects modulation of prefrontal and striatal function during attentional salience processing","volume":"69","author":"Bhattacharyya","year":"2012","journal-title":"Arch. Gen. Psychiatr."},{"key":"10.1016\/j.neuropharm.2020.108178_bib3","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1016\/j.peptides.2005.03.026","article-title":"Hypotensive effects of hemopressin and bradykinin in rabbits, rats and mice. A comparative study","volume":"26","author":"Blais","year":"2005","journal-title":"Peptides"},{"key":"10.1016\/j.neuropharm.2020.108178_bib4","doi-asserted-by":"crossref","first-page":"952","DOI":"10.1016\/j.bcp.2012.01.004","article-title":"Monohydroxylated metabolites of the K2 synthetic cannabinoid JWH-073 retain intermediate to high cannabinoid 1 receptor (CB1R) affinity and exhibit neutral antagonist to partial agonist activity","volume":"83","author":"Brents","year":"2012","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108178_bib5","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0080440","article-title":"Cannabinoid CB2 receptors regulate central sensitization and pain responses associated with osteoarthritis of the knee joint","volume":"8","author":"Burston","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.neuropharm.2020.108178_bib6","doi-asserted-by":"crossref","first-page":"3911","DOI":"10.1111\/bph.14461","article-title":"GpTx-1 and [Ala(5) , Phe(6) , Leu(26) , Arg(28) ]GpTx-1, two peptide NaV 1.7 inhibitors: analgesic and tolerance properties at the spinal level","volume":"175","author":"Chen","year":"2018","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108178_bib7","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1016\/j.neulet.2009.03.029","article-title":"Neuropeptide VF-associated satiety involves mu and kappa but not delta subtypes of opioid receptors in chicks","volume":"455","author":"Cline","year":"2009","journal-title":"Neurosci. Lett."},{"key":"10.1016\/j.neuropharm.2020.108178_bib8","doi-asserted-by":"crossref","first-page":"2322","DOI":"10.1111\/ejn.14407","article-title":"Modulatory effects of cannabinoids on brain neurotransmission","volume":"50","author":"Cohen","year":"2019","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2020.108178_bib9","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1016\/j.neuroscience.2006.02.074","article-title":"Immunohistochemical localization of cannabinoid type 1 and vanilloid transient receptor potential vanilloid type 1 receptors in the mouse brain","volume":"139","author":"Cristino","year":"2006","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2020.108178_bib10","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/j.peptides.2004.10.026","article-title":"Antinociceptive action of hemopressin in experimental hyperalgesia","volume":"26","author":"Dale","year":"2005","journal-title":"Peptides"},{"key":"10.1016\/j.neuropharm.2020.108178_bib11","doi-asserted-by":"crossref","first-page":"1123","DOI":"10.1517\/13543784.2014.918603","article-title":"Cannabinoids in pain management: CB1, CB2 and non-classic receptor ligands","volume":"23","author":"Davis","year":"2014","journal-title":"Expet Opin. Invest. Drugs"},{"key":"10.1016\/j.neuropharm.2020.108178_bib12","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1016\/S0091-3057(97)00249-9","article-title":"Hypothermic effects of neuropeptide FF analogues in mice","volume":"58","author":"Desprat","year":"1997","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2020.108178_bib13","doi-asserted-by":"crossref","first-page":"605","DOI":"10.1016\/S0026-895X(25)09876-1","article-title":"Determination and characterization of a cannabinoid receptor in rat brain","volume":"34","author":"Devane","year":"1988","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108178_bib14","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.neuropharm.2011.09.013","article-title":"Effects of neuropeptide FF system on CB(1) and CB(2) receptors mediated antinociception in mice","volume":"62","author":"Fang","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2020.108178_bib15","doi-asserted-by":"crossref","first-page":"7","DOI":"10.1016\/j.pbb.2014.11.013","article-title":"Anxiogenic-like effects induced by hemopressin in rats","volume":"129","author":"Fogaca","year":"2015","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2020.108178_bib16","doi-asserted-by":"crossref","first-page":"7621","DOI":"10.1073\/pnas.130181897","article-title":"A substance P-opioid chimeric peptide as a unique nontolerance-forming analgesic","volume":"97","author":"Foran","year":"2000","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2020.108178_bib17","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1186\/1744-8069-9-32","article-title":"Analgesic effect of a mixed T-type channel inhibitor\/CB2 receptor agonist","volume":"9","author":"Gadotti","year":"2013","journal-title":"Mol. Pain"},{"key":"10.1016\/j.neuropharm.2020.108178_bib18","doi-asserted-by":"crossref","first-page":"3020","DOI":"10.1096\/fj.09-132142","article-title":"Novel endogenous peptide agonists of cannabinoid receptors","volume":"23","author":"Gomes","year":"2009","journal-title":"Faseb. J."},{"key":"10.1016\/j.neuropharm.2020.108178_bib19","doi-asserted-by":"crossref","first-page":"8224","DOI":"10.1021\/jm4005626","article-title":"Therapeutic utility of cannabinoid receptor type 2 (CB(2)) selective agonists","volume":"56","author":"Han","year":"2013","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2020.108178_bib20","doi-asserted-by":"crossref","first-page":"316","DOI":"10.1124\/jpet.113.209866","article-title":"Antinociceptive effects of central administration of the endogenous cannabinoid receptor type 1 agonist VDPVNFKLLSH-OH [(m)VD-hemopressin(alpha)], an N-terminally extended hemopressin peptide","volume":"348","author":"Han","year":"2014","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2020.108178_bib21","doi-asserted-by":"crossref","first-page":"1360","DOI":"10.1213\/ANE.0000000000000921","article-title":"Neuropeptide VF enhances cannabinoid agonist WIN55,212-2-induced antinociception in mice","volume":"121","author":"Han","year":"2015","journal-title":"Anesth. Analg."},{"key":"10.1016\/j.neuropharm.2020.108178_bib22","doi-asserted-by":"crossref","first-page":"14228","DOI":"10.1073\/pnas.96.25.14228","article-title":"HU-308: a specific agonist for CB(2), a peripheral cannabinoid receptor","volume":"96","author":"Hanus","year":"1999","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2020.108178_bib23","doi-asserted-by":"crossref","first-page":"20588","DOI":"10.1073\/pnas.0706980105","article-title":"Hemopressin is an inverse agonist of CB1 cannabinoid receptors","volume":"104","author":"Heimann","year":"2007","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2020.108178_bib24","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1016\/S0024-3205(03)00390-4","article-title":"Design of novel peptide ligands which have opioid agonist activity and CCK antagonist activity for the treatment of pain","volume":"73","author":"Hruby","year":"2003","journal-title":"Life Sci."},{"key":"10.1016\/j.neuropharm.2020.108178_bib25","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0022-3565(25)20260-9","article-title":"The antinociceptive effects of spinally administered neuropeptide Y in the rat: systematic studies on structure-activity relationship","volume":"258","author":"Hua","year":"1991","journal-title":"J. Pharmacol. Exp. Therapeut."},{"key":"10.1016\/j.neuropharm.2020.108178_bib26","doi-asserted-by":"crossref","first-page":"10529","DOI":"10.1073\/pnas.1834309100","article-title":"Activation of CB2 cannabinoid receptors by AM1241 inhibits experimental neuropathic pain: pain inhibition by receptors not present in the CNS","volume":"100","author":"Ibrahim","year":"2003","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2020.108178_bib27","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1038\/npp.2015.148","article-title":"A cannabinoid CB1 receptor-positive allosteric modulator reduces neuropathic pain in the mouse with No psychoactive effects","volume":"40","author":"Ignatowska-Jankowska","year":"2015","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2020.108178_bib28","doi-asserted-by":"crossref","first-page":"446","DOI":"10.1016\/j.neuroscience.2013.07.040","article-title":"Activation of spinal cannabinoid CB2 receptors inhibits neuropathic pain in streptozotocin-induced diabetic mice","volume":"250","author":"Ikeda","year":"2013","journal-title":"Neuroscience"},{"key":"10.1016\/j.neuropharm.2020.108178_bib29","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1016\/j.pharmthera.2009.12.005","article-title":"Cannabinoids and the gut: new developments and emerging concepts","volume":"126","author":"Izzo","year":"2010","journal-title":"Pharmacol. Ther."},{"key":"10.1016\/j.neuropharm.2020.108178_bib30","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.ejphar.2005.10.020","article-title":"Cannabinoid CB2 receptor agonist activity in the hindpaw incision model of postoperative pain","volume":"527","author":"LaBuda","year":"2005","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108178_bib31","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1016\/S0014-2999(02)02053-8","article-title":"Modulation of gastric emptying and gastrointestinal transit in rats through intestinal cannabinoid CB(1) receptors","volume":"450","author":"Landi","year":"2002","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108178_bib32","doi-asserted-by":"crossref","first-page":"420","DOI":"10.3389\/fphar.2018.00420","article-title":"Emerging role of (Endo)Cannabinoids in migraine","volume":"9","author":"Leimuranta","year":"2018","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108178_bib33","doi-asserted-by":"crossref","first-page":"1864","DOI":"10.1111\/bph.13489","article-title":"BN-9, a chimeric peptide with mixed opioid and neuropeptide FF receptor agonistic properties, produces nontolerance-forming antinociception in mice","volume":"173","author":"Li","year":"2016","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108178_bib34","doi-asserted-by":"crossref","first-page":"891","DOI":"10.1111\/nmo.12789","article-title":"Central administrations of hemopressin and related peptides inhibit gastrointestinal motility in mice","volume":"28","author":"Li","year":"2016","journal-title":"Neuro Gastroenterol. Motil."},{"key":"10.1016\/j.neuropharm.2020.108178_bib35","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1016\/j.clim.2006.11.002","article-title":"CB2 cannabinoid receptor agonist, JWH-015, triggers apoptosis in immune cells: potential role for CB2-selective ligands as immunosuppressive agents","volume":"122","author":"Lombard","year":"2007","journal-title":"Clin. Immunol."},{"key":"10.1016\/j.neuropharm.2020.108178_bib36","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1038\/346561a0","article-title":"Structure of a cannabinoid receptor and functional expression of the cloned cDNA","volume":"346","author":"Matsuda","year":"1990","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2020.108178_bib37","doi-asserted-by":"crossref","first-page":"1471","DOI":"10.1016\/S0196-9781(01)00468-5","article-title":"Structure-activity relationships of neuropeptide FF: role of C-terminal regions","volume":"22","author":"Mazarguil","year":"2001","journal-title":"Peptides"},{"key":"10.1016\/j.neuropharm.2020.108178_bib38","doi-asserted-by":"crossref","first-page":"4552","DOI":"10.1021\/ja00993a072","article-title":"A stereospecific synthesis of (-)-delta 1- and (-)-delta 1(6)-tetrahydrocannabinols","volume":"89","author":"Mechoulam","year":"1967","journal-title":"J. Am. Chem. Soc."},{"key":"10.1016\/j.neuropharm.2020.108178_bib39","doi-asserted-by":"crossref","first-page":"6523","DOI":"10.1021\/jm058225d","article-title":"Designed multiple ligands. An emerging drug discovery paradigm","volume":"48","author":"Morphy","year":"2005","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2020.108178_bib40","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1038\/365061a0","article-title":"Molecular characterization of a peripheral receptor for cannabinoids","volume":"365","author":"Munro","year":"1993","journal-title":"Nature"},{"key":"10.1016\/j.neuropharm.2020.108178_bib41","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/0196-9781(95)02137-X","article-title":"Neuropeptide FF reduces food intake in rats","volume":"17","author":"Murase","year":"1996","journal-title":"Peptides"},{"key":"10.1016\/j.neuropharm.2020.108178_bib42","doi-asserted-by":"crossref","first-page":"2515","DOI":"10.1038\/npp.2013.157","article-title":"Role of CB2 cannabinoid receptors in the rewarding, reinforcing, and physical effects of nicotine","volume":"38","author":"Navarrete","year":"2013","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.neuropharm.2020.108178_bib43","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1124\/pr.58.3.2","article-title":"The endocannabinoid system as an emerging target of pharmacotherapy","volume":"58","author":"Pacher","year":"2006","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuropharm.2020.108178_bib44","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1016\/j.ejphar.2015.10.016","article-title":"Effects of neuropeptide FF and related peptides on the antinociceptive activities of VD-hemopressin(alpha) in naive and cannabinoid-tolerant mice","volume":"767","author":"Pan","year":"2015","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108178_bib45","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.2174\/1381612822666160125114144","article-title":"Opioid and cannabinoid system in food intake","volume":"22","author":"Pomorska","year":"2016","journal-title":"Curr. Pharmaceut. Des."},{"key":"10.1016\/j.neuropharm.2020.108178_bib46","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1517\/13543776.2012.682570","article-title":"Selective cannabinoid receptor 2 modulators: a patent review 2009--present","volume":"22","author":"Riether","year":"2012","journal-title":"Expert Opin. Ther. Pat."},{"key":"10.1016\/j.neuropharm.2020.108178_bib47","doi-asserted-by":"crossref","first-page":"8547","DOI":"10.1074\/jbc.M212030200","article-title":"Novel natural peptide substrates for endopeptidase 24.15, neurolysin, and angiotensin-converting enzyme","volume":"278","author":"Rioli","year":"2003","journal-title":"J. Biol. Chem."},{"key":"10.1016\/j.neuropharm.2020.108178_bib48","doi-asserted-by":"crossref","first-page":"128","DOI":"10.3109\/07853890.2016.1145794","article-title":"Cannabinoids: medical implications","volume":"48","author":"Schrot","year":"2016","journal-title":"Ann. Med."},{"key":"10.1016\/j.neuropharm.2020.108178_bib49","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/j.pnpbp.2017.07.012","article-title":"Antinociceptive effects of HUF-101, a fluorinated cannabidiol derivative","volume":"79","author":"Silva","year":"2017","journal-title":"Prog. Neuro-Psychopharmacol. Biol. Psychiatry"},{"key":"10.1016\/j.neuropharm.2020.108178_bib50","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1073\/pnas.0502090103","article-title":"RF9, a potent and selective neuropeptide FF receptor antagonist, prevents opioid-induced tolerance associated with hyperalgesia","volume":"103","author":"Simonin","year":"2006","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2020.108178_bib51","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.ejps.2017.06.004","article-title":"Importance of N- and C-terminal residues of substance P 1-7 for alleviating allodynia in mice after peripheral administration","volume":"106","author":"Skogh","year":"2017","journal-title":"Eur. J. Pharmaceut. Sci."},{"key":"10.1016\/j.neuropharm.2020.108178_bib52","doi-asserted-by":"crossref","first-page":"437","DOI":"10.1016\/bs.apha.2017.05.003","article-title":"Cannabinoids and pain: sites and mechanisms of action","volume":"80","author":"Starowicz","year":"2017","journal-title":"Adv. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108178_bib53","doi-asserted-by":"crossref","first-page":"2751","DOI":"10.1007\/s00213-015-3907-0","article-title":"Cannabinoid withdrawal in mice: inverse agonist vs neutral antagonist","volume":"232","author":"Tai","year":"2015","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2020.108178_bib54","doi-asserted-by":"crossref","first-page":"990","DOI":"10.1016\/j.peptides.2005.07.024","article-title":"Structure-activity relationships of neuropeptide FF and related peptidic and non-peptidic derivatives","volume":"27","author":"Vyas","year":"2006","journal-title":"Peptides"},{"key":"10.1016\/j.neuropharm.2020.108178_bib55","doi-asserted-by":"crossref","first-page":"10198","DOI":"10.1021\/acs.jmedchem.6b01181","article-title":"Structure-based optimization of multifunctional agonists for opioid and neuropeptide FF receptors with potent nontolerance forming analgesic activities","volume":"59","author":"Wang","year":"2016","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.neuropharm.2020.108178_bib56","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1016\/j.neuropharm.2017.06.015","article-title":"The cannabinoid system and pain","volume":"124","author":"Woodhams","year":"2017","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2020.108178_bib57","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1111\/bph.14848","article-title":"The multifunctional peptide DN-9 produced peripherally acting antinociception in inflammatory and neuropathic pain via mu- and kappa-opioid receptors","volume":"177","author":"Xu","year":"2020","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2020.108178_bib58","doi-asserted-by":"crossref","first-page":"7757","DOI":"10.1073\/pnas.82.22.7757","article-title":"Isolation, sequencing, synthesis, and pharmacological characterization of two brain neuropeptides that modulate the action of morphine","volume":"82","author":"Yang","year":"1985","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.neuropharm.2020.108178_bib59","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.peptides.2016.09.012","article-title":"Activation of NPFF2 receptor stimulates neurite outgrowth in Neuro 2A cells through activation of ERK signaling pathway","volume":"86","author":"Yu","year":"2016","journal-title":"Peptides"},{"key":"10.1016\/j.neuropharm.2020.108178_bib60","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.aat.2013.12.006","article-title":"Cannabis in pain medicine still has a long way to go","volume":"51","author":"Yuan","year":"2013","journal-title":"Acta Anaesthesiol. Taiwanica"},{"key":"10.1016\/j.neuropharm.2020.108178_bib61","doi-asserted-by":"crossref","first-page":"630","DOI":"10.1016\/j.bmc.2019.01.003","article-title":"Discovery of two novel branched peptidomimetics containing endomorphin-2 and RF9 pharmacophores: synthesis and neuropharmacological evaluation","volume":"27","author":"Zhang","year":"2019","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.neuropharm.2020.108178_bib62","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1016\/j.npep.2016.12.006","article-title":"Pharmacological characterization of rat VD-hemopressin(alpha), an alpha-hemoglobin-derived peptide exhibiting cannabinoid agonist-like effects in mice","volume":"63","author":"Zheng","year":"2017","journal-title":"Neuropeptides"},{"key":"10.1016\/j.neuropharm.2020.108178_bib63","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.brainres.2017.12.013","article-title":"CB1 cannabinoid receptor agonist mouse VD-hemopressin(alpha) produced supraspinal analgesic activity in the preclinical models of pain","volume":"1680","author":"Zheng","year":"2018","journal-title":"Brain Res."},{"key":"10.1016\/j.neuropharm.2020.108178_bib64","doi-asserted-by":"crossref","DOI":"10.3390\/ijms19030833","article-title":"Cannabinoid receptors and the endocannabinoid system: signaling and function in the central nervous system","volume":"19","author":"Zou","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.neuropharm.2020.108178_bib65","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1007\/s00011-017-1040-8","article-title":"Probucol attenuates overt pain-like behavior and carrageenan-induced inflammatory hyperalgesia and leukocyte recruitment by inhibiting NF-small ka, CyrillicB activation and cytokine production without antioxidant effects","volume":"66","author":"Zucoloto","year":"2017","journal-title":"Inflamm. Res."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002839082030246X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S002839082030246X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,21]],"date-time":"2025-09-21T07:03:54Z","timestamp":1758438234000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S002839082030246X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,9]]},"references-count":65,"alternative-id":["S002839082030246X"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2020.108178","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2020,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"VF-13, a chimeric peptide of VD-hemopressin(\u03b1) and neuropeptide VF, produces potent antinociception with reduced cannabinoid-related side effects","name":"articletitle","label":"Article Title"},{"value":"Neuropharmacology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.neuropharm.2020.108178","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2020 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}],"article-number":"108178"}}